Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.

Molecular biology reports - 1 Aug 2022

Folta Adam, Sasinkova Marketa, Durinikova Anna, Drncova Marie, Weinbergerova Barbora, Mayer Jiri, Jeziskova Ivana

Abstract excerpt

BACKGROUND: NPM1 plasmid standards are required for absolute quantification of minimal residual disease in acute myeloid leukemia patients. The standards are usually obtained, next to commercially constructed gene fragments, from transgenic bacteria colonies. However, this procedure is laborious and very time consuming. METHODS AND RESULTS: We have developed a PCR method that speeds up, simplifies, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm, Residual

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Plasmids

Source

Identifiers

PMID: 35716280
DOI: 10.1007/s11033-022-07363-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.PMID 35716280Read ↗

Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.Semantic proximity Read ↗

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesSemantic proximity Read ↗

Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.Semantic proximity Read ↗

NPM1 for MRD? Droplet Like It's Hot!Semantic proximity Read ↗

Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.Semantic proximity Read ↗

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.Semantic proximity Read ↗

Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Clinical Laboratory Validation and Implementation of Quantitative, Real-Time PCR-based Monitoring of NPM1 Type A MutationSemantic proximity Read ↗

Validation of a Multiplex mRNA- and gDNA-Based Droplet Digital PCR Assay in Acute Myeloid Leukemia Patients with an NPM1 Mutation.Semantic proximity Read ↗

Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.